Prothena_RGB_fullcolor.jpg
Prothena to Participate in Upcoming Healthcare Conferences
September 01, 2022 16:20 ET | Prothena Corporation plc
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena Announces Appointment of Biotechnology Industry Leader Helen S. Kim to its Board of Directors
September 01, 2022 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena_RGB_fullcolor.jpg
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
August 08, 2022 16:05 ET | Prothena Corporation plc
Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1...
Prothena_RGB_fullcolor.jpg
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics...
Prothena_RGB_fullcolor.jpg
Prothena to Report Second Quarter 2022 Financial Results on August 8th
August 01, 2022 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena_RGB_fullcolor.jpg
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:16 ET | Prothena Corporation plc
DUBLIN, Ireland, July 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics...
Prothena_RGB_fullcolor.jpg
Prothena to Participate in Jefferies Healthcare Conference
June 02, 2022 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on...
Prothena_RGB_fullcolor.jpg
Prothena Reports First Quarter 2022 Financial Results and Business Highlights
May 05, 2022 16:05 ET | Prothena Corporation plc
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class,...
Prothena_RGB_fullcolor.jpg
Prothena to Report First Quarter 2022 Financial Results on May 5th
April 28, 2022 16:05 ET | Prothena Corporation plc
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built...
Prothena_RGB_fullcolor.jpg
Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
April 26, 2022 08:30 ET | Prothena Corporation plc
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, April 26, 2022 ...